LGND
NASDAQ · Pharmaceuticals
Ligand Pharmaceuticals
$293.15
-6.99 (-2.33%)
Financial Highlights (FY 2026)
Revenue
269.56M
Net Income
125.13M
Gross Margin
94.6%
Profit Margin
46.4%
Rev Growth
+11.0%
D/E Ratio
0.44
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.6% | 94.6% | 55.6% | 55.6% |
| Operating Margin | 15.3% | 13.8% | 24.0% | 26.4% |
| Profit Margin | 46.4% | 44.1% | 27.4% | 27.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 269.56M | 242.91M | 944.72M | 909.17M |
| Gross Profit | 254.92M | 229.72M | 525.52M | 505.75M |
| Operating Income | 41.22M | 33.43M | 226.35M | 240.08M |
| Net Income | 125.13M | 101.49M | 258.92M | 249.74M |
| Gross Margin | 94.6% | 94.6% | 55.6% | 55.6% |
| Operating Margin | 15.3% | 13.8% | 24.0% | 26.4% |
| Profit Margin | 46.4% | 44.1% | 27.4% | 27.5% |
| Rev Growth | +11.0% | +11.0% | +8.5% | +8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 912.00M | 912.00M | 257.30M | 195.72M |
| Total Equity | 2.08B | 2.08B | 1.39B | 1.23B |
| D/E Ratio | 0.44 | 0.44 | 0.19 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 74.11M | 63.45M | 346.84M | 320.13M |
| Free Cash Flow | — | — | 167.31M | 167.23M |